In this context, it is notable that dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the treatment of patients with type 2 diabetes, decreased the incidence of AF/AFL in those patients [13]. Here, SLC5A2 is linked to atrial fibrillation.